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Cells of adult mammals can be converted (reprogrammed) to new cells. In one approach, adult cells are con-
verted to pluripotent stem cells, followed by differentiation to regenerate new cell types. Alternatively, adult
cells may be directly converted into other mature cells or progenitors. We discuss and compare these two
approaches with particular emphasis on the latter and its relevance for regenerative medicine.Introduction
A primary goal of regenerative medicine is to produce new cells
to repair or replace diseased and damaged tissues. Among the
many innovative ideas proposed to achieve this goal, a particu-
larly interesting one involves remaking existing adult cells into
new ones by converting them from one cell type to another.
For example, abundant human cells such as dermal fibroblasts
and adipocytes could be harvested and converted into other,
medically important cells such as neurons, cardiomyocytes, or
pancreatic b cells. These new cells may then be transplanted
back into the same patient. Remaking adult cells in this way
has the advantage of providing a fully immunologically matched
graft; the patient would be getting his or her own cells back. In
short, this approach may be viewed as repurposing a piece of
adult skin, for example, into part of the heart or pancreas.
Adult Cells Are Highly Stable
A clear challenge to remaking adult cells is that mature cells of
adult organisms are remarkably stable. Differentiated cells main-
tain their state for years and rarely, if ever, switch to a new state.
And indeed, switching or flip-flopping from one cell state to an-
other would have dire consequences, including the formation
of cancerous cell types. Cells arrive at a stable position by a pro-
gressive or sequential restriction in their options, beginning as
a pluripotent embryonic cell and ending up at the mature differ-
entiated state. Conrad H. Waddington, a pioneering embryolo-
gist, vividly depicts this process of cell differentiation as a ball
rolling down valleys in an epigenetic landscape. The ball rolls
downhill through bifurcated valleys of possible developmental
paths, or ‘‘chreodes’’ as he called them, that lead to different
cell types that can be realized (Waddington, 1957). At the end,
a cell finds itself at the bottom of a valley in a stable differentiated
state (Figure 1A).
The ball (cell) at the end of the developmental process, at the
bottom of the epigenetic landscape, is in a state often described
as one of terminal differentiation. There are numerous lines of ev-
idence suggesting that, once a cell has reached this state, it is
permanent or nearly so; indeed, it is sometimes accompanied
by the inability to divide any further, as in the case of red blood
cells, keratinocytes, andmany kinds of neurons. For those differ-
entiated cells that do divide, of which there are many examples,
a terminally differentiated cell produces daughters that are also
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and Leblond, 1960; Tsubouchi et al., 1987), and drawing from
our own work, adult pancreatic b cells divide to give rise to
new b cells, thereby providing a simple mechanism for organ
maintenance (Dor et al., 2004). Aside from aberrant cases ob-
served in some cancers, the idea that adult cells are plastic,
that they can switch fates from one cell type to another, has little
observational or experimental support. There was a recent and
brief period in the stem cell field where adult stem cell plasticity,
essentially the opposite of stability, was being promoted based
on the idea that certain adult stem cells were not restricted in
their fates and could easily adopt new fates depending on their
environment (reviewed by Weissman et al., 2001). For example,
it was suggested that blood stem cells could give rise to multiple
lineages other than blood (Brazelton et al., 2000; Gussoni et al.,
1999; Krause et al., 2001; Lagasse et al., 2000). Despite initial in-
dications that this might be possible, convincing evidence for the
lack of plasticity in blood stem cells has been presented (Wagers
and Weissman, 2004). In other words, blood stem cells differen-
tiate into blood, and neither they nor their daughters form other
kinds of cells. To be more cautious, if plasticity in adult blood
stem cells does occur, it does not appear to happen at an appre-
ciable rate with any in vivo developmental or physiological signif-
icance. Thus, Waddington’s epigenetic landscape is an apt
description of cell differentiation, with an ever-increasing restric-
tion in options culminating in a stable differentiated state.
Different Approaches to Convert Cells
The observations discussed above reflect on an understanding
of what happens during normal development and the physiolog-
ical maintenance of an adult. At the same time, it is, of course,
important to appreciate the remarkable potential of cells, even
terminally differentiated cells, as revealed by experimental ma-
nipulation. Pioneering experiments in amphibian in the 1960s,
in particular those of Gurdon, revealed that the identity of a ma-
ture cell can be reversed and its daughter cells reconfigured by
transplanting the nucleus of an adult cell into the cytoplasm of
an unfertilized egg. Following nuclear transplantation, the differ-
entiation process is reversed completely, and the adult cell’s nu-
cleus is returned to a pluripotent state from which it can go on
and develop into an entire animal (Gurdon, 2006). Following
this striking demonstration using frog cells, reprogramming by
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Schematic diagrams of development and reprogramming of
cells in the epigenetic landscape.
(A) In normal development, a pluripotent cell, such as an em-
bryonic stem cell (green ball), rolls down bifurcating valleys,
which represent all possible developmental paths. The cell
makes a series of choices and differentiates into a mature
cell (blue ball) at the bottom of the valley.
(B) During pluripotent reprogramming, which includes somatic
cell nuclear transfer (SCNT) and formation of induced pluripo-
tent stem (iPS) cells, the entire developmental process is re-
versed, and a differentiated cell is returned to a pluripotent
state. This is represented by the ball (cell) rolling from the bot-
tom of the valley backward all the way to the top.
(C) Lineage reprogramming includes dedifferentiation and transdifferentiation, where a mature cell takes a step backward to a progenitor stage (cyan ball) or
converts directly to another mature cell (yellow ball). Painting of the epigenetic landscape adapted from Waddington (1957).somatic nuclear transfer (SCNT) has been accomplished inmany
mammalian species (Hochedlinger and Jaenisch, 2006). These
impressive demonstrations of the inherent potency of cells
have led to a search for reprogramming factors that can directly
convert differentiated cells back to a pluripotent stage. In one
approach, this culminated in the discovery by Yamanaka and
colleagues that adult skin cells can be induced to become plurip-
otent stem cells (iPSCs) in culture by a small set of transcription
factors (Takahashi et al., 2007; Takahashi and Yamanaka, 2006;
Yu et al., 2007). Both SCNT and iPSC reprogramming results in
the formation of pluripotent stem cells, and for the purpose of
this review, we refer to them collectively as pluripotent reprog-
ramming. In Waddington’s depiction, these reprogramming
events would be equivalent to the ball (cell) rolling back up to
the top of the hill to where it started (Figure 1B).
By completely reversing the developmental process, pluripo-
tent reprogramming removes all or nearly all epigenetic marks
laid down during development. The resulting cell type, a pluripo-
tent stem cell, is not suitable for direct therapeutic applications.
Instead, the stem cells must be differentiated in vitro into mature
or progenitor cells such as neurons, cardiomyocytes, or osteo-
blasts, which can then be used in cellular therapies or drug
screening. Directed differentiation of stem cells (embryonic
stem cells or tissue-specific fetal and adult stem cells) is a very
active area of research whose primary goal is to guide the fate
choice of a multipotent cell toward a particular progeny. As
such, it is a process that parallels normal development and
does not involve the gain of additional potency. We therefore
do not consider directed differentiation as a form of reprogram-
ming and will not discuss it in detail in this essay.
Pluripotent reprogramming, followed by directed differentia-
tion, offers a powerful strategy to regenerate any cell type in the
body. Furthermore, this strategy is amicable for patient-specific
therapies. Together, they form a very important part of the tech-
nological platform upon which regenerative medicine can be
built.
In addition to pluripotent reprogramming, there are other re-
programming approaches that more directly convert mature
cells to progenitors or other mature cells without going back to
or through a pluripotent stage. For example, during salamander
limb regeneration, adult skin, muscle, and cartilage cells dedif-
ferentiate to a progenitor stage, which then redifferentiate to cre-
ate a new limb (Brockes and Kumar, 2002). After injury,
pigmented epithelial cells of the iris form lens cells in a process
called transdifferentiation (Eguchi and Okada, 1973). Both dedif-ferentiation and transdifferentiation represent reprogramming
strategies that do not involve reverting cells back to a pluripotent
stage. In this way, many of the epigenetic marks of the starting
cell types are preserved. In addition, the final cell types of these
reprogramming processes, progenitors and mature cells, may
be directly used in applications such as cell replacement thera-
pies. We refer here to these approaches as lineage reprogram-
ming (Orkin and Zon, 2008) (Figure 1C), in distinction to pluripo-
tent reprogramming.
There are yet other types of reprogramming events, for exam-
ple, conversions between progenitor cells as in transdetermina-
tion (Hadorn, 1968) or certain types of metaplasia (Slack, 2007).
These reprogramming events, similar to lineage reprogramming,
do not result in the formation of pluripotent stem cells and likely
involve only partial alteration to the epigenetic marks. Thus, we
include these reprogramming phenomena under lineage reprog-
ramming.
Lineage reprogramming has long fascinated biologists in part
because of the promise of harnessing this phenomenon for re-
generativemedicine whereby abundant adult cells could be con-
verted directly into therapeutically important cell types for tissue
repair and regeneration. Despite years of research, relatively little
is known about how lineage reprogramming is accomplished. If
one is to exploit this phenomenon to make new cells for thera-
peutic purposes, it would be important to know, for example,
which genes and factors are sufficient to promote lineage re-
programming. In this regard, important insights come from stud-
ies on master regulator genes. For example, MyoD, a transcrip-
tion factor critical in specifying the skeletal muscle lineage, can
convert cultured embryonic fibroblast, chondroblast, and retinal
epithelial cells into contracting muscle cells (Choi et al., 1990).
Similarly, B lymphocytes can be converted to macrophages by
the transcription factor CEBP (Xie et al., 2004), and inner ear sup-
port cells reprogrammed to hair cells by Math1 (Izumikawa et al.,
2005; Zheng and Gao, 2000). As significant as these studies are
in emphasizing the power of master regulator genes in determin-
ing and converting cell lineages, they do not provide a general
strategy for reprogramming differentiated cells.
A Broad Strategy for Adult Lineage Reprogramming
To formulate a broad strategy for lineage reprogramming, an im-
portant clue comes from regeneration, namely that the recrea-
tion of adult structures is preceded by reactivation of embryonic
genes that normally function during organ development (Iovine,
2007; Slack et al., 2008; Tanaka, 2003). This recapitulation of
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bryonic genes would be important for reprogramming adult cells,
a hypothesis consistent with known examples of lineage reprog-
ramming where the factors used are well-studied developmental
regulators (Choi et al., 1990; Cobaleda et al., 2007; Kondo and
Raff, 2000; Laiosa et al., 2006; Orkin and Zon, 2008; Xie et al.,
2004; Zheng and Gao, 2000).
With this principle in mind, our laboratory recently developed
a strategy for adult lineage reprogramming and used it to directly
convert mature pancreatic exocrine cells to endocrine b cells in
adult animals (Zhou et al., 2008). Both exocrine cells and b cells
derive from embryonic pancreatic endoderm, yet they have dis-
tinctmorphology and perform very different functions (Murtaugh,
2007). To define the instructive reprogramming factors, we fo-
cused on transcription factors (TF), a class of genes particularly
enriched in embryonic cell fate regulators. A genome-wide ex-
pression analysis of >1100 TFs on the developing pancreas
revealed cohorts of TFs with specific expression in distinct pro-
genitor cell types (Zhou et al., 2007). About 30 TFs are expressed
in pancreatic and endocrine progenitors, the two precursor cells
that directly lead to the b cell lineage. Of these 30 genes, analysis
of knockout studies pointed to 9/30 genes that appear to be re-
quired for b cell fate specification. Using an in vivo assay to test
the nine candidate genes, we progressively eliminated individual
factors from this gene pool and eventually identified just three
factors that together reprogram adult exocrine cells to b cells
(Zhou et al., 2008).
Is this strategy likely applicable to other cell types? Decades of
painstaking developmental studies have already detailed the lin-
eages and regulator genes for many cell types. This rich knowl-
edge, together with well-designed assays, should allow the
reprogramming strategy used in our study to be broadly applied
in other contexts. For example, there is a large body of knowl-
edge about the lineages of neurons and their associated glial
cells, and the genetic codes that govern their generation during
embryogenesis are being elucidated (Hochstim et al., 2008;
Jessell, 2000; Zhou and Anderson, 2002). Similarly, the lineages
and critical developmental factors for cardiomyocytes have be-
come much better understood (Martin-Puig et al., 2008; Olson,
2004), and there is an increasing volume of work being done to
establish lineages for many other cell types. Taking the motor
neuron as one example, this strategy would suggest that it
may be possible to convert central nervous system glial cells
into motor neurons, an attractive possibility in diseases of motor
neuron deficiency such as Amyotrophic lateral sclerosis (ALS) or
spinal cord injuries. And acute injuries such as heart attacks
could be remedied by using cardiomyocytes reprogrammed
from skeletal muscle or skin fibroblasts. Whether such optimistic
prediction can be realized should become clear in the next few
years. Cell types such as motor neurons and cardiomyocytes
could also be derived with other approaches, such as directed
differentiation from embryonic stem cells or differentiation from
fetal or adult progenitor cells. It remains to be seen which one
of these approaches will eventually yield therapeutically useful
cells.
It is prudent to be cautious about interpreting a change in gene
expression as lineage reprogramming or cell type conversion.
For example, some reported cellular ‘‘conversions’’ are achieved
by ectopic expression of powerful transcription factors that are
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sion of, for example, the insulin or muscle actin gene. Constitu-
tive expression of multiple such factors can force a specific tran-
scription program onto the host cell without stable cell type
conversion. A true lineage reprogramming event is most useful
if it requires only a transient expression of the reprogramming
factors, and the resulting cell should make a full phenotypic
switch without exhibiting a hybrid phenotype. In this context,
we note that cell fusion can produce heterokaryons with a hybrid
or mixed phenotype. A further consideration is that cells con-
verted in vitro, where cellular morphology and physiology are
prone to change, would ideally be further tested for their stability
and function by transplantation for in vivo analysis.
In principle, an adult cell may be reprogrammed into another
mature cell or a progenitor/stem cell with the lineage reprogram-
ming strategy. For example, a pancreatic exocrine cell may be
converted to a b cell, or an endocrine progenitor that produces
all pancreatic endocrine cell types. Likewise, an astroglia in the
nervous system may be converted directly to a neuron, or in-
stead to a neural stem cell that produces all neural cell types.
To define the reprogramming factors for the different ‘‘end’’
cell types, two central questions stand out. First, what genes
are good candidate factors to test? And second, should the
test be carried out in vivo or in vitro?
While each lineage reprogramming experiment must be de-
signed in a case-by-case manner, some general guidelines
may be suggested. For example, important developmental reg-
ulator genes expressed in the lineage of the final cell type are
good candidates for reprogramming factors. The best candi-
dates would be those that exhibit clear knockout phenotypes,
where deletion of the gene results in severe developmental de-
fects or complete absence of the particular cell type. Lineage
analysis, by determining precisely which cells express the candi-
date gene and at what times during development, is also very in-
structive. If knockout studies and lineage analyses are not avail-
able, gene expression data could be used to point to selected
gene families such as transcription factors of the homeobox
and bHLH families, and extracellular factors such as Wnt and
Notch families, which often play important roles in development.
Emphasis should be placed on selecting candidate factors from
progenitors or immature cells, rather than focusing solely on fully
differentiated cells. This selection criterion is supported by
known examples of lineage reprogramming where the reprog-
ramming factors, such asMyoD, Ngn3, andMath1, have expres-
sion in immature rather than mature cells.
Once a list of candidate reprogramming factors is selected,
they can be tested in vivo or in vitro. An in vitro culture system
offers the advantage of controlled conditions where large num-
bers of factors can be tested in parallel. This approach, however,
depends on the availability of optimized culture conditions
which, for many cell types, are still lacking. Alternatively, candi-
date factors can be tested directly in vivo, as done in the b cell
reprogramming study (Zhou et al., 2008). Experiments in living
animals aremore demanding, and only a small number of factors
may be tested. In addition, it is currently unclear howmuch influ-
ence the cells’ native environment, including interactions with
their neighboring cells, has in ‘‘stabilizing’’ the starting cell pop-
ulation and thereby making the in vivo conversion more difficult.
Furthermore, it is unknown whether reprogramming factors
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cells directly in vivo.
Role of the Niche
For cellular conversions that occur in vivo, the role of the cellular
environment, or niche, should be considered. The differentiated
state of a mature cell is most stable when the cell resides in its
native environment, for example, a neuron in the nervous sys-
tem. When ectopically induced in a different organ system, a
mature cell may exhibit altered phenotype or function. It may
therefore be advantageous to inducemature cells directly in their
native tissue environment during in vivo reprogramming.
Figure 2. Possible Strategies to Facilitate Lineage Reprogramming
of Cells
(A) A hypothetical cell lineage where tissue stem cells (S1, S2) give rise to pro-
genitor cells (P1–P3), which generate different mature cell types (M1–M7). In
both transdifferentiation and dedifferentiation, different start cell types may
be reprogrammed to the same final cell type. In principle, a closely related
cell type should be easier to convert (dark arrow) than a more distantly related
cell type (light arrow).
(B) Reprogramming of one cell (orange) to another (pink) may be achieved by
ectopic expression of factors (green star) or deletion/knockdown of factors
(black X), or both. Reagents that loosen chromatin structures or enhance pro-
liferation are predicted to enhance cell type conversions. The factors and re-
agents used may be genes, siRNA, or chemical compounds.Compared to mature cells, progenitors and stem cells may
have even more stringent requirements for their niches (Fuchs
et al., 2004; Jones and Wagers, 2008). If there are suitable cul-
ture conditions for the progenitor/stem cells, then the experi-
ment can be carried out in vitro, as in the case of converting
oligodendrocyte progenitors to neural stem cells (Kondo and
Raff, 2000). If the reprogramming is performed directly in vivo,
however, an environmental niche must be available. Otherwise,
even if the conversion is successful, the resulting progenitor/
stem cell may immediately undergo apoptosis or differentiation.
Perhaps due to this reason, there have been very few reports of
in vivo reprogramming in adult that produce progenitor/stem
cells. Deletion of Pax5 leads to conversion of mature B lympho-
cytes to uncommitted hematopoietic progenitors in adult ani-
mals (Cobaleda et al., 2007). This success is likely aided by the
fact that circulating blood cells have ready access to existing
niche environments (lymph nodes, in this particular example).
Nevertheless, an in vivo strategy should be possible for any tis-
sue that harbors adult progenitor/stem cells such as the hemato-
poietic system, the nervous system, skeletal muscle, skin, and
others.
Strategies that May Facilitate Adult Lineage
Reprogramming
Current examples of lineage reprogramming have primarily re-
lied on ectopic expression of reprogramming factors. These fac-
tors must establish a new epigenetic program in the host cell and
erase the original program. There is evidence suggesting that de-
letion of factors that support the original epigenetic state of host
cells can facilitate their phenotypic conversion. As discussed
above, deletion of Pax5, a factor critical in establishing B cell
identity, allows conversion of B lymphocyte to uncommitted
hematopoietic progenitors (Cobaleda et al., 2007). Removal of
Polycomb and Trithorax epigenetic factors also facilitates leg-
to-wing transdetermination in fly (Klebes et al., 2005). These
studies suggest that a reprogramming strategy that couples ec-
topic expression of reprogramming factors with a simultaneous
reduction of host cell maintenance factors may be most efficient
(Figure 2B). The example of B cell dedifferentiation further sug-
gests that, in some cases, removal of host cell maintenance fac-
tors by itself might be sufficient to convert cells (Figure 2B). The
deletion/knockdown-based strategy may be particularly impor-
tant for dedifferentiation efforts aimed at generating progenitor
or tissue-specific stem cells from mature cells, which are be-
lieved to possess factors that are dedicated to maintaining the
differentiated state. The identity of such maintenance factors,
however, remains largely unknown.
In addition to improving the chances of success of achieving
lineage reprogramming by ‘‘loosening’’ the maintenance factors
that define a terminal state, some cell types might be more ame-
nable to reprogramming toward a given target lineage than
others. That is, to generate a given cell type through lineage re-
programming, different starting cell populations may be used.
For example, to produce pancreatic b cells, pancreatic exocrine
or duct cells may serve as the starting points, or perhaps liver
cells, a closely related endoderm cell type, may be used. One
could even stretch this idea to skin fibroblasts, the product of
a different germ layer, for a starting population. The ease of con-
verting these different cell types to b cells, however, will likely be
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Pluripotent Reprogramming (SCNT, iPSCs) Lineage Reprogramming (Trans-, Dedifferentiation)
Instructive factors known known in a few cases
largely the same for different cell types likely different for each cell type
Epigenetic changes removal of nearly all epigenetic marks removal of some epigenetic marks
Final cell product pluripotent stem cells mature and progenitor cells
not suitable for direct therapeutic application suitable for direct therapeutic application
In vivo regeneration not possible possible
Suitable target cells all cell types may be limited to closely related cell typesquite different. Distinct cell types are defined by their unique
combination of epigenetic marks that are accumulated progres-
sively during the numerous developmental steps. Closely related
cell types, such as the pancreatic exocrine cell and b cell, share
much of their developmental history and therefore also share
much of their epigenetic makeup, or epigenome (Bernstein
et al., 2007). This epigenetic similarity shouldmake it easier to in-
terconvert these two cell types, as only a small portion of their
epigenomes would have to be rearranged. More distantly related
cells have more epigenetic differences, including DNA and his-
tone modifications, which can make chromosomal regions rela-
tively inaccessible and difficult to unravel. Thus, to produce
a particular cell type by lineage reprogramming, it may be desir-
able to choose a starting cell type that is closely related to the
final cell (Figure 2A).
There will be cases, however, where it is not possible or con-
venient to obtain a closely related starting population, in which
case, several additional measures may be helpful. For example,
chemicals, such as HDAC inhibitors, may be used to ‘‘loosen’’
chromatin structures (Xu et al., 2008). In addition, cells are
thought to be most vulnerable to epigenetic change at mitosis,
when chromosomes decondense and the nuclear envelope
breaks down, allowing easier access to the chromosomes for re-
programming factors (Hochedlinger and Jaenisch, 2006). Stimu-
lating cell proliferation may therefore facilitate cell type conver-
sions (Figure 2B).
It is notable that current examples of lineage reprogramming
mostly occur between closely related cell types (Choi et al.,
1990; Cobaleda et al., 2007; Kondo and Raff, 2000; Laiosa
et al., 2006; Orkin and Zon, 2008; Xie et al., 2004; Zheng and
Gao, 2000). Even with the additional facilitating measures as dis-
cussed above, it is unclear whether distantly related cell types
can indeed be fully converted with a lineage reprogramming
approach.
Comparing the Main Reprogramming Approaches
Recent advances in lineage reprogramming promise the devel-
opment of powerful alternative regeneration strategies based
on transdifferentiation and dedifferentiation that will complement
pluripotent reprogramming and iPSC technology. The two major
reprogramming approaches differ in several important aspects
(Table 1). For example, factors that direct pluripotent reprogram-
ming have already been discovered, and these factors appear
capable of reprogramming a wide variety of cell types to stem
cells (Aoi et al., 2008; Hanna et al., 2008; Kim et al., 2008; Stadt-
feld et al., 2008). In contrast, lineage reprogramming factors are
likely to be specific for each cell type, and most of the instructive
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of lineage reprogramming, such as progenitor cells and mature
cells, are suitable for direct clinical applications, whereas the fi-
nal product of pluripotent reprogramming, ESCs and iPSCs, de-
pend on directed differentiation to convert them to mature or
progenitor cells.
An advantage of lineage reprogramming is the possibility of
converting cells directly in vivo for in situ regeneration and repair.
For example, pancreatic exocrine cells reprogrammed into
b cells may be induced to join existing islets to replenish b cells
that were destroyed by autoimmune attacks in type 1 diabetes.
Or neurons converted from glial cells could join existing neuronal
networks to repair specific nervous system damages, as in Par-
kinson’s disease or spinal cord injury. These in vivo repair and re-
generation strategies are not possible with iPSC-based reprog-
ramming approaches, if for no other reason than the fact that
iPSCs would form teratomas in vivo (Table 1).
Another potential advantage of lineage reprogramming ap-
proaches is the possibility that by taking one step back, or
a step sideways, only part of the numerous epigenetic marks es-
tablished during development need be reset or rearranged. In
contrast, iPSC generation necessitates the removal of nearly
all epigenetic marks, and these would need to be correctly re-
established during in vitro differentiation of iPSCs (Table 1).
A potential limitation of the lineage reprogramming approach
is that it may be most suitable for closely related cell types. At
present, it is unclear whether distantly related cell types can be
fully converted with lineage reprogramming. Pluripotent reprog-
ramming, together with directed differentiation, should be able to
produce all cell types in the body.
ESCs and iPSCs have nearly unlimited capacity to proliferate
in culture. On one hand, this provides abundant starting material
to produce desired cell types. On the other, the many cycles of
proliferation required in the derivation of iPSCs and their subse-
quent differentiation may select for fast-growing, culture-adap-
ted cells that harbor subtle genetic mutations. Such changes
could result in unstable phenotypes, including cancer, when
cells are transplanted in vivo. Lineage reprogramming, particu-
larly between closely related cell types, should require fewer pro-
liferation steps and thus may reduce the chance of mutations
(Table 1).
Remaining Challenges for Lineage Reprogramming
In terms of developing patient-specific therapies, reprogram-
ming mature cells from patients, rather than immature cells
from embryos, may be the most practical approach. However,
the terminal differentiation steps that create mature cells are
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a differentiated program. Consequently, it may be more difficult
to reprogram mature cells than immature cells. For example, a
review of the hematopoietic system finds multiple examples of
reprogramming embryonic cells, but very few examples using
mature blood cells (Orkin and Zon, 2008). In addition, it has
been shown that mature cells are more difficult to be reprog-
rammed into a pluripotent state than immature cells (Blelloch
et al., 2006; Hanna et al., 2008). Currently, rather little is known
about the epigenetic programs that are specifically activated
during terminal differentiation, and there is reason to believe
that a better understanding of these mechanisms would allow
for the design of better strategies to reprogram mature cells. At
this time, efforts of lineage reprogramming are largely focused
on identifying effective reprogramming factors, which will likely
vary depending on each target and final cell type. This is, of
course, only the first step, and hopefully more will soon be
learned about the molecular basis for the reported lineage re-
programming events (Choi et al., 1990; Cobaleda et al., 2007;
Kondo and Raff, 2000; Laiosa et al., 2006; Orkin and Zon,
2008; Xie et al., 2004; Zheng and Gao, 2000).
Lineage reprogramming strategies have been employed to
treat diseases in animal models. For example, inner ear hair
cells converted from support cells improve the hearing of deaf
animals (Izumikawa et al., 2005), whereas b cells converted
from pancreatic exocrine cells can ameliorate hyperglycemic
conditions (Zhou et al., 2008). Significant challenges remain,
however, to translate these and other lineage reprogramming
approaches to clinical applications in humans. To list just
a few, protein-based reprogramming factors, such as transcrip-
tion factors, will have to be replaced by safer alternatives such
as small molecules; potential risk factors, such as partially re-
programmed cells that may be prone to malignant transforma-
tions, must be properly addressed; and the reprogrammed cells
may need to be organized into tissues or even organs before
clinical use.
The last decade has seen an explosion of interest in regener-
ative medicine. Many strategies are being pursued to generate
clinically useful new cells. These strategies include the identifica-
tion and differentiation of fetal and adult stem/progenitor cells
and the generation and directed differentiation of ESCs and
iPSCs, among others. Significant progress has been made on
these fronts. Although the phenomena of lineage reprogramming
have long been known, systematic studies on the feasibility of
exploiting lineage reprogramming for regenerative medicine
have just begun. Despite the many challenges that lay ahead,
we are optimistic that lineage reprogramming offers an attractive
approach with distinct advantages to become an important part
of the future of regenerative medicine.
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